Description
Non-Fucosylated Anti-Human FGFR2b (Bemarituzumab/ FPA144) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Gastrointestinal Cancer, Metastatic Gastric Cancer; Transitional Cell Carcinoma of the Genitourinary Tract (Bladder Cancer);
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FGFR2b antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
Fibroblast growth factor receptor 2
Background
Fibroblast growth factor receptor 2 (FGFR2) also known as CD332 (cluster of differentiation 332) is a protein that in humans is encoded by the FGFR2 gene residing on chromosome 10. FGFR2 is a receptor for fibroblast growth factor.
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform.
Alternative Names
FGFR2, BBDS, BEK, BFR-1, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, fibroblast growth factor receptor 2
Cellular Localization
Cell membrane
Involvement in Disease
Diseases associated with FGFR2 include Pfeiffer Syndrome and Crouzon Syndrome. Among its related pathways are RET signaling and Signaling by FGFR2 in disease.
Function
As the cell surface receptor of fibroblast growth factor, protein tyrosine kinase plays a vital role in regulating cell proliferation, differentiation, migration and apoptosis and regulating embryonic development. Normal embryonic pattern, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development are required. It plays a vital role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is necessary for normal bone development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylate PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signal cascades. The activation of PLCG1 leads to the production of cell signaling molecules diacylglycerol and inositol 1,4,5-triphosphate. Phosphorylation of FRS2 triggers the recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates the activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and MAP kinase signaling pathways and AKT1 signaling pathway. FGFR2 signal transduction is down-regulated due to ubiquitination, internalization and degradation. Mutations that cause constitutive kinases to activate or impair normal FGFR2 maturation, internalization and degradation can lead to abnormal signaling. Over-expressed FGFR2 promotes the activation of STAT1.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
Bemarituzumab/ FPA144
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Gastrointestinal Cancer, Metastatic Gastric Cancer; Transitional Cell Carcinoma of the Genitourinary Tract (Bladder Cancer);
